Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

Part of paid clinical trials in New Brunswick, New Jersey.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Study ID
NCT03405155
Phase
PHASE2
Status
Completed

Conditions

  • Melanoma (Skin)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date
Jan 17, 2018
Status verified
May 2026
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025

Study Design

Enrollment
26 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (nivolumab)
    Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Recurrence-free Survival [ Time Frame: Approximately 22 months (2 years) ]

Locations (4)

FacilityCityStateZIPSite coordinators
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08903-
Columbia UniversityNew YorkNew York10032-
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphiaPennsylvania19107-
Univeristy of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in New Brunswick, NJ

By research site
Rutgers Cancer Institute of New Jersey· New Brunswick, NJColumbia University· New York, NYSidney Kimmel Cancer Center at Thomas Jefferson University· Philadelphia, PAUniveristy of Pennsylvania· Philadelphia, PA

Related Studies